Defence And Security Tenders

Completion of a Non-Excl. Discount Agreement According to § 130C Paragraph 1 Sgb V for Elbasvir, Grazoprevir Atc Code: J05ap54 for the Period from 03/01/2023 to 02/28/2025

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Everolimus (Atc L01eg02)

Completion of a Non-Excl. Discount Agreement According to § 130A Para. 8 Sgb V for Diabetes Tests Glucose Atc Code: V04ca02 for the Period from 03/01/2023 to 02/28/2025 Without Doctor and Insured Letter

Completion of a Non-Excl. Discount Agreement According to § 130C Paragraph 1 Sgb V for Evolocumab Atc Code: C10ax13 for the Period from 03/01/2023 to 02/28/2025

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Etanercept (Atc Code According to Who: L04ab01)

Completion of a Non-Excl. Discount Agreement According to § 130C Paragraph 1 Sgb V for Mepolizumab Atc Code: R03dx09 for the Period from 03/01/2023 to 02/28/2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Naloxegol, Atc Code: A06ah03 for the Period from 03/01/2023 to 02/28/2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Fentanyl Dihydrogen Citrate, Atc Code: N02ab03 for the Period from 03/01/2023 to 02/28/2025

Drugs Containing the Active Substance Dasatinib (Atc: L01ea02)

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Dasatinib (L01ea02) as Part of an Open House Model.